trending Market Intelligence /marketintelligence/en/news-insights/trending/czIw4443paVh8Vt_POZpUg2 content esgSubNav
In This List

Generex Biotechnology acquires 51% of NY-based wound gel maker Olaregen

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Generex Biotechnology acquires 51% of NY-based wound gel maker Olaregen

Generex Biotechnology Corp. completed its purchase of a 51% stake in Olaregen Therapeutix Inc.

New York-based Olaregen is a regenerative medicine company preparing to launch its wound conforming gel matrix Excellagen, which has received clearance from the U.S. Food and Drug Administration to treat wounds such as diabetic ulcers and surgical wounds.

Under the deal's terms, Generex is paying $400,000 up front and could make an additional $11.6 million in milestone payments.

Generex Biotechnology, which develops cancer therapies, medical devices and diagnostics, recently acquired Regentys Corp., a Miami-based regenerative drug company manufacturing treatments targeting gastrointestinal disorders.